Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria

NCT02633046 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Focal Segmental Glomerulosclerosis

Interventions

DRUG: Acthar Gel

Sponsor

Mallinckrodt ARD LLC